PPHVanEck Pharmaceutical ETF
Fund Description
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS®US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
-
Fund Ticker
PPH -
Exchange
NASDAQ -
Inception Date
12/20/2011 -
ETF Structure
Physical -
Administrator
Van Eck Associates -
Index Ticker
MVPPHTR -
Index Rebalancing
Quarterly
as of 07/01/22
-
30-Day SEC Yield
1.68% -
Total Net Assets
$590.7M -
Number of Holdings
25 -
Options
Available -
Gross Expense Ratio2
0.35% -
Net Expense Ratio/TER2
0.35% -
Distribution Frequency
Quarterly -
Next Distribution Date
09/30/2022
Key Points
- Highly Liquid Companies
Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
- Industry Leaders
Index methodology favors the largest companies in the industry
- Global Scope
Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
Trading Information
-
Fund Ticker
PPH -
Index Total Return Ticker
MVPPHTR -
NAV
PPHNV -
Intraday NAV (IIV)4
PPHIV -
Shares Outstanding
7,638,138 -
Estimated Cash
PPHEU -
Total Cash
PPHTC -
CUSIP
92189F692 -
ISIN
US92189F6925
Fees and Expenses2
-
Management Fee
0.35% -
Other Expenses
-- -
Acquired Fund Fees and Expenses
-- -
Gross Expense Ratio
0.35% -
Fee Waivers and
--
Expense Reimbursement -
Net Expense Ratio/TER2
0.35%
2'Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2023.'
Investment Professionals
Peter Liao, CFA
- Portfolio Manager and Head of Equity ETFs
- Oversees the Equity ETF Investment Management Team including development and management of index replication and optimization strategies
- Joined VanEck in 2005
- CFA charterholder; member of the CFA Society New York
- BA, Mathematics and Economics, New York University
Guo Hua (Jason) Jin
- Portfolio Manager and Analyst for Equity ETFs
- Joined VanEck in 2007
- Prior to his current role, held a portfolio administration position at VanEck
- Previously, Portfolio Analyst at Evaluation Associates
- BS, Business Administration (concentration in Financial Analysis), State University of New York at Buffalo
Griffin Driscoll
- Analyst for Equity ETFs
- Joined VanEck in 2018
- Prior to joining VanEck, ETF Basket Operations Analyst at JPMorgan
- BS, Finance, Providence College
Ralph Lasta
- Analyst for Equity ETFs
- Joined VanEck in 2019
- Prior to VanEck, Intermediate Representative, Exchange Traded Funds at BNY Mellon.
- BS, Accounting, Hunter College
Performance History: Average Annual Total Returns* (%)
1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR |
LIFE 12/20/11 |
|
---|---|---|---|---|---|---|---|---|
PPH (NAV) | 2.10 | 5.15 | 3.49 | 11.71 | 15.14 | 8.61 | 10.27 | 10.07 |
PPH (Share Price) | 2.17 | 5.20 | 3.50 | 11.74 | 15.15 | 8.61 | 10.28 | 10.17 |
MVPPHTR (Index) | 2.07 | 5.14 | 3.44 | 11.44 | 14.84 | 8.44 | 10.17 | 9.96 |
Performance Differential (NAV - Index) | 0.03 | 0.01 | 0.05 | 0.27 | 0.30 | 0.17 | 0.10 | 0.11 |
1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR |
LIFE 12/20/11 |
|
---|---|---|---|---|---|---|---|---|
PPH (NAV) | 5.24 | 3.58 | 3.58 | 17.62 | 11.51 | 9.66 | 9.80 | 10.25 |
PPH (Share Price) | 5.35 | 3.64 | 3.64 | 17.57 | 11.53 | 9.69 | 9.82 | 10.36 |
MVPPHTR (Index) | 5.22 | 3.53 | 3.53 | 17.27 | 11.19 | 9.47 | 9.68 | 10.13 |
Performance Differential (NAV - Index) | 0.02 | 0.05 | 0.05 | 0.35 | 0.32 | 0.19 | 0.12 | 0.12 |
Top 10 Holdings (%) as of 05/31/22 Daily Holdings
to view
full data
Holding Name |
Ticker
|
Shares
|
Market Value (US$) |
% of Net Assets |
---|---|---|---|---|
Eli Lilly & Co |
LLY US |
87,288 |
27,359,551 | 5.67 |
Merck & Co Inc |
MRK US |
294,881 |
27,137,898 | 5.63 |
Bristol-Myers Squibb Co |
BMY US |
336,695 |
25,403,638 | 5.27 |
Novartis Ag |
NVS US |
279,235 |
25,393,631 | 5.27 |
Astrazeneca Plc |
AZN US |
379,600 |
25,235,808 | 5.23 |
Pfizer Inc |
PFE US |
470,544 |
24,957,654 | 5.17 |
Mckesson Corp |
MCK US |
74,663 |
24,540,981 | 5.09 |
Viatris Inc |
VTRS US |
1,990,806 |
24,427,190 | 5.06 |
Johnson & Johnson |
JNJ US |
135,444 |
24,316,261 | 5.04 |
Novo Nordisk A/S |
NVO US |
218,337 |
24,104,405 | 5.00 |
Top 10 Total (%) | 52.43 |
Country Weightings (%) as of 05/31/22
-
Country
% of Net Assets -
■
United States
66.81 -
■
United Kingdom
9.78 -
■
Switzerland
5.27 -
■
Denmark
5.00 -
■
France
4.88 -
■
Japan
4.28 -
■
Israel
3.68 -
■
Ireland
0.22 -
■
Other/Cash
0.09
Sector Weightings (%) as of 05/31/22
-
Sector
% of Net Assets -
■
Health Care
99.9 -
■
Other/Cash
0.1